Genocea Biosciences Inc (NASDAQ:GNCA) Stock Slumps After Initial Data from GEN-011 Phase 1/2a Trial

April 13, 2022

Biopharmaceutical company Genocea Biosciences Inc (NASDAQ:GNCA) has seen its stock decline sharply in recent days and the situation remained the same yesterday as it declined by another 18% amidst a heavy selloff. The decline in the Genocea over the past week stretched to a staggering 65% following yesterday’s fall. Trading Data On Tuesday, GNCA stock went down 18.33% to $0.49 with more than 5.17 million shares, compared to its average…

Read More >>